Search results for: 'detection of pollution carbonaceous particles biological samples'

Accelerated reforms due to COVID-19 and technologically advanced sample-in-answer-out portable, web-connected, encrypted devices that provide results in a few minutes changed the diagnostic healthcare industry. Decentralized testing empowers clinicians to make lifesaving decisions for the patient. It shortens supply chain lag time, saves costs of i...

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

10 May 2018  |  North America  |  Market Research

Global Tissue Diagnostics Market, Forecast to 2022

Liquid Biopsy for Therapy Monitoring and Reimbursement Cuts Impede Long-term Prospects of Tissue Diagnostics Market

Infographics

×

Key Issues Addressed

Tissue diagnostic techniques are used to recognize specific antigens in preserved tissues. The process includes slicing thin tissue samples that are treated with a hematoxylin and eosin (H&E) stain, and then are formalin-fixed paraffin-embedded (FFPE) to diagnose tumors and other histopathology specimens. This has traditionally required skilled pat...

Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the out...

16 Feb 2021  |  North America  |  Market Research

Smartphone-based Saliva Testing and Self-monitoring of Blood Glucose Driving the Digital POCT Market

Mobility Ecosystem Holds Bold Promise to Expand Patients’ Access to Care

Infographics

×

Smartphone-based devices and associated tools are becoming the ideal next-generation point-of-care testing (POCT) solutions for in vitro diagnostics. The global COVID-19 pandemic has led to frugal innovations in POCT. The World Health Organization (WHO) has endorsed POCT as the topmost research priority in response to the COVID-19 outbreak. Digital...

This Frost Radar benchmarks companies offering digital pathology solutions for hospitals and laboratories and discusses opportunities in clinical, pharma, CRO, and research applications. Digital pathology solutions cover all aspects of workflow including sample collection and preparation, image acquisition and integrated image storage, and anal...

12 Aug 2021  |  North America  |  Frost Radar

Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

23 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...